Xavier Alsina-Restoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xavier Alsina-Restoy has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Fernanda Hernandez-Gonzalez
Pulmonology Department, Hospital Clinic, 08402 Barcelona, Spain
6 shared publications - Jacobo Sellares
Hospital Clinic, Barcelona, Spain
6 shared publications - Isabel Blanco
Department of Pulmonary Medicine, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
5 shared publications - Rodrigo Torres-Castro
Department of Physical Therapy, Faculty of Medicine, University of Chile, Santiago 8380453, Chile
5 shared publications - Alejandro Frino-García
Department of Pulmonology, Hospital Clínic de Barcelona, Barcelona, Spain
4 shared publications - Elena Gimeno-Santos
ISGlobal, Barcelona, Spain
4 shared publications
Latest Publications
- Open Access
Checkpoint Inhibitor Pneumonitis: Key Insights for Pulmonologists
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, offering significant efficacy and a generally favorable safety profile. However, they are associated with a spectrum of immune-related adverse events (irAEs), among which pneumonitis stands out due to its relatively high mortality. This condition is characterized by nonspecific clinical manifestations and a broad differential diagnosis, often requiring the involvement of pulmonologists for accurate diagnosis and management. Given its potential severity, it is crucial for pulmonologists to be well-versed in recognizing and addressing checkpoint inhibitor pneumonitis (CIP). In this narrative review, we examine reported cases of pneumonitis in patients with various types of cancer treated with ICIs. The article explores the mechanisms of action of ICIs, the underlying pathophysiology of pneumonitis, associated risk factors, clinical presentation, diagnostic approaches, and current treatment strategies, intended to support pulmonologists in improving early detection and implementing evidence-based management of this potentially life-threatening complication.
Open AccessCheckpoint Inhibitor Pneumonitis: Key Insights for Pulmonologists
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, offering significant efficacy and a generally favorable safety profile. However, they are associated with a spectrum of immune-related adverse events (irAEs), among which pneumonitis stands out due to its relatively high mortality. This condition is characterized by nonspecific clinical manifestations and a broad differential diagnosis, often requiring the involvement of pulmonologists for accurate diagnosis and management. Given its potential severity, it is crucial for pulmonologists to be well-versed in recognizing and addressing checkpoint inhibitor pneumonitis (CIP). In this narrative review, we examine reported cases of pneumonitis in patients with various types of cancer treated with ICIs. The article explores the mechanisms of action of ICIs, the underlying pathophysiology of pneumonitis, associated risk factors, clinical presentation, diagnostic approaches, and current treatment strategies, intended to support pulmonologists in improving early detection and implementing evidence-based management of this potentially life-threatening complication.
- Open Access
- 1 September 2025
- Published by MDPI AG in Journal of Respiration
- Vol. 5 (3) , 14
Evolving Concepts in Progressive Pulmonary Fibrosis: A Clinical Update
Progressive pulmonary fibrosis (PPF) is a clinical syndrome associated with worsening quality of life and increased mortality among patients with various interstitial lung diseases. This review aims to update the concepts and criteria that adequately define PPF, aiming to facilitate earlier recognition and optimize clinical management. Fibrosing interstitial lung disease (ILD-f) can progress over time despite optimal management of the underlying conditions. Current criteria for defining PPF include worsening respiratory symptoms, decline in pulmonary function tests (particularly forced vital capacity and diffusing capacity), and radiographic progression over a 1-year follow-up period. However, implementation of these criteria in clinical practice poses challenges. This review discusses the limitations of current evaluation methods and proposes future directions, including the need for validated symptom assessment tools, standardization of pulmonary function testing, and improvements in quantitative radiological evaluation methods.
- 1 September 2025
- Published by MDPI AG in Journal of Respiration
- Vol. 5 (3) , 14
Open AccessEvolving Concepts in Progressive Pulmonary Fibrosis: A Clinical Update
Progressive pulmonary fibrosis (PPF) is a clinical syndrome associated with worsening quality of life and increased mortality among patients with various interstitial lung diseases. This review aims to update the concepts and criteria that adequately define PPF, aiming to facilitate earlier recognition and optimize clinical management. Fibrosing interstitial lung disease (ILD-f) can progress over time despite optimal management of the underlying conditions. Current criteria for defining PPF include worsening respiratory symptoms, decline in pulmonary function tests (particularly forced vital capacity and diffusing capacity), and radiographic progression over a 1-year follow-up period. However, implementation of these criteria in clinical practice poses challenges. This review discusses the limitations of current evaluation methods and proposes future directions, including the need for validated symptom assessment tools, standardization of pulmonary function testing, and improvements in quantitative radiological evaluation methods.
- 9 January 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 54 (5) , e14151
Six‐minute walking distance and desaturation–distance ratio in allogeneic stem cell transplantation
Background: Most patients with haematological malignancies who undergo allogeneic haematopoietic stem cell transplant (HSCT) receive chemotherapy before the transplant to control the disease. Certain chemotherapy drugs can cause lung toxicity. Conversely, in patients with chronic respiratory conditions, the 6‐min walking test (6MWT) and the desaturation–distance ratio (DDR) have demonstrated prognostic significance. Our objective was to determine whether the 6MWD and DDR, assessed prior to HSCT, have a prognostic impact on survival at 24 months post‐HSCT.Methods: A prospective experimental study was conducted in consecutive patients referred for allogeneic HSCT at Hospital Clinic, Barcelona, Spain. A complete functional respiratory study, including the 6MWT and DDR, was conducted prior to admission. The area under the curve (AUC) and cut‐off points were calculated. Data on patients' characteristics, HSCT details, main events, with a focus on lung complications, and survival at 24 months were analysed.Results: One hundred and seventy‐five patients (39% women) with mean age of 48 ± 13 years old were included. Before HSCT, forced vital capacity and forced expiratory volume in the first second were 96% ± 13% predicted and 92% ± 14% predicted, respectively; corrected diffusing capacity for carbon monoxide 79% ± 15% predicted; 6MWD was 568 ± 83 m and DDR of .27 (.20–.41). The cut‐off points for 6MWD and DDR were 566 m, [.58 95% CI (.51–.64)], p = .024 and .306, [.63 95% CI (.55–.70)], p = .0005, respectively. The survival rate at 24 months was 55%.Conclusion: Our results showed that individuals who exhibit a 6MWD shorter than 566 ms or a decline in DDR beyond .306 experienced reduced survival rates at 24 months after HSCT.
- 9 January 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 54 (5) , e14151
Six‐minute walking distance and desaturation–distance ratio in allogeneic stem cell transplantation
Background: Most patients with haematological malignancies who undergo allogeneic haematopoietic stem cell transplant (HSCT) receive chemotherapy before the transplant to control the disease. Certain chemotherapy drugs can cause lung toxicity. Conversely, in patients with chronic respiratory conditions, the 6‐min walking test (6MWT) and the desaturation–distance ratio (DDR) have demonstrated prognostic significance. Our objective was to determine whether the 6MWD and DDR, assessed prior to HSCT, have a prognostic impact on survival at 24 months post‐HSCT.Methods: A prospective experimental study was conducted in consecutive patients referred for allogeneic HSCT at Hospital Clinic, Barcelona, Spain. A complete functional respiratory study, including the 6MWT and DDR, was conducted prior to admission. The area under the curve (AUC) and cut‐off points were calculated. Data on patients' characteristics, HSCT details, main events, with a focus on lung complications, and survival at 24 months were analysed.Results: One hundred and seventy‐five patients (39% women) with mean age of 48 ± 13 years old were included. Before HSCT, forced vital capacity and forced expiratory volume in the first second were 96% ± 13% predicted and 92% ± 14% predicted, respectively; corrected diffusing capacity for carbon monoxide 79% ± 15% predicted; 6MWD was 568 ± 83 m and DDR of .27 (.20–.41). The cut‐off points for 6MWD and DDR were 566 m, [.58 95% CI (.51–.64)], p = .024 and .306, [.63 95% CI (.55–.70)], p = .0005, respectively. The survival rate at 24 months was 55%.Conclusion: Our results showed that individuals who exhibit a 6MWD shorter than 566 ms or a decline in DDR beyond .306 experienced reduced survival rates at 24 months after HSCT.
- Open Access
- 7 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 13832
Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression
(1) The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial. We hypothesized that peripheral blood immune phenotypes will be different in IPF patients and may relate to the disease severity and progression. (2) Whole blood flow cytometry staining was performed at diagnosis in 32 IPF patients, and in 32 age- and smoking-matched healthy controls. Thirty-one IPF patients were followed up for one year and categorized as stable or progressors based on lung function, deterioration and/or death. At 18–60 months, immunophenotypes were characterized again. (3) The main results showed that: (1) compared to matched controls, at diagnosis, patients with IPF showed more neutrophils, CD8+HLA-DR+ and CD8+CD28− T cells, and fewer B lymphocytes and naïve T cells; (2) in IPF, circulating neutrophils, eosinophils and naïve T cells were associated with lung function abnormalities; (3) patients whose disease progressed during the 12 months of follow-up showed evidence of cytotoxic dysregulation, with increased CD8+CD28− T cells, decreased naïve T cells and an inverted CD4/CD8 ratio at baseline; and (4) blood cell alterations were stable over time in survivors. (4) IPF is associated with abnormalities in circulating immune cells, particularly in the cytotoxic cell domain. Patients with progressive IPF, despite antifibrotic therapy, present an over-activated and exhausted immunophenotype at diagnosis, which is maintained over time.
- 7 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 13832
Open AccessBlood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression
(1) The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial. We hypothesized that peripheral blood immune phenotypes will be different in IPF patients and may relate to the disease severity and progression. (2) Whole blood flow cytometry staining was performed at diagnosis in 32 IPF patients, and in 32 age- and smoking-matched healthy controls. Thirty-one IPF patients were followed up for one year and categorized as stable or progressors based on lung function, deterioration and/or death. At 18–60 months, immunophenotypes were characterized again. (3) The main results showed that: (1) compared to matched controls, at diagnosis, patients with IPF showed more neutrophils, CD8+HLA-DR+ and CD8+CD28− T cells, and fewer B lymphocytes and naïve T cells; (2) in IPF, circulating neutrophils, eosinophils and naïve T cells were associated with lung function abnormalities; (3) patients whose disease progressed during the 12 months of follow-up showed evidence of cytotoxic dysregulation, with increased CD8+CD28− T cells, decreased naïve T cells and an inverted CD4/CD8 ratio at baseline; and (4) blood cell alterations were stable over time in survivors. (4) IPF is associated with abnormalities in circulating immune cells, particularly in the cytotoxic cell domain. Patients with progressive IPF, despite antifibrotic therapy, present an over-activated and exhausted immunophenotype at diagnosis, which is maintained over time.
- Open Access
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3293
Pulmonary Rehabilitation in Sarcoidosis: A Systematic Review and Meta-analysis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3293
Open AccessPulmonary Rehabilitation in Sarcoidosis: A Systematic Review and Meta-analysis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3931
Reference Equation for the Six-minute Walk Test in the Ecuadorian Population
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3931
Reference Equation for the Six-minute Walk Test in the Ecuadorian Population
- Open Access
Assessment of Exercise Capacity in Post-COVID-19 Patients: How Is the Appropriate Test Chosen?
There is a wide range of sequelae affecting COVID-19 survivors, including impaired physical capacity. These sequelae can affect the quality of life and return to work of the active population. Therefore, one of the pillars of following-up is the evaluation of physical capacity, which can be assessed with field tests (such as the six-minute walk test, the one-minute standing test, the Chester step test, and the shuttle walking test) or laboratory tests (such as the cardiopulmonary exercise test). These tests can be performed in different contexts and have amply demonstrated their usefulness in the assessment of physical capacity both in post-COVID-19 patients and in other chronic respiratory, metabolic, cardiologic, or neurologic diseases. However, when traditional tests cannot be performed, physical function can be a good substitute, especially for assessing the effects of an intervention. For example, the Short Physical Performance Battery assessment and the Timed Up and Go assessment are widely accepted in older adults. Thus, the test should be chosen according to the characteristics of each subject.
Open AccessAssessment of Exercise Capacity in Post-COVID-19 Patients: How Is the Appropriate Test Chosen?
There is a wide range of sequelae affecting COVID-19 survivors, including impaired physical capacity. These sequelae can affect the quality of life and return to work of the active population. Therefore, one of the pillars of following-up is the evaluation of physical capacity, which can be assessed with field tests (such as the six-minute walk test, the one-minute standing test, the Chester step test, and the shuttle walking test) or laboratory tests (such as the cardiopulmonary exercise test). These tests can be performed in different contexts and have amply demonstrated their usefulness in the assessment of physical capacity both in post-COVID-19 patients and in other chronic respiratory, metabolic, cardiologic, or neurologic diseases. However, when traditional tests cannot be performed, physical function can be a good substitute, especially for assessing the effects of an intervention. For example, the Short Physical Performance Battery assessment and the Timed Up and Go assessment are widely accepted in older adults. Thus, the test should be chosen according to the characteristics of each subject.
- 5 December 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 206, 107070
Does arterial oxygenation during exercise add prognostic value in pulmonary arterial hypertension?
- 5 December 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 206, 107070
Does arterial oxygenation during exercise add prognostic value in pulmonary arterial hypertension?
- 11 March 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Effects of pulmonary rehabilitation on patients with sarcoidosis: a systematic review and meta-analysis of randomised controlled trials
Review question / Objective: Is pulmonary rehabilitation an effective intervention in patients with sarcoidosis? Condition being studied: Sarcoidosis. Eligibility criteria: We will include studies published until March 2022. The population studied must be adults (>18y) with diagnosis of sarcoidosis that performed a structured program of pulmonary rehabilitation. We will include only outpatients. They must be patients with stable disease and without exacerbation for at least one month.
- 11 March 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Effects of pulmonary rehabilitation on patients with sarcoidosis: a systematic review and meta-analysis of randomised controlled trials
Review question / Objective: Is pulmonary rehabilitation an effective intervention in patients with sarcoidosis? Condition being studied: Sarcoidosis. Eligibility criteria: We will include studies published until March 2022. The population studied must be adults (>18y) with diagnosis of sarcoidosis that performed a structured program of pulmonary rehabilitation. We will include only outpatients. They must be patients with stable disease and without exacerbation for at least one month.